By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq
Caring Brands Announces Pricing of ,000,000 Million Uplisting to Nasdaq
Health

Caring Brands Announces Pricing of $4,000,000 Million Uplisting to Nasdaq

GlobeNews Wire
Last updated: 13/11/2025 10:36 AM
GlobeNews Wire
Published: 13/11/2025
Share
SHARE

FORT PIERCE, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — Caring Brands, Inc. (“Caring Brands” or the “Company”), a wellness consumer products company offering several over-the-counter (OTC) and cosmetic consumer products, today announced the pricing of its underwritten U.S. public offering of 1,000,000 common shares at a public offering price of $4.00 per common share for aggregate gross proceeds of approximately US $4,000,000, prior to deducting underwriting discounts and offering expenses (the “Offering”).

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 150,000 common shares at the public offering price, less the underwriting discounts and commissions. The Offering is expected to close on November 14, 2025, subject to customary closing conditions.

In connection with the Offering, Caring Brands has received approval to list its common shares on the Nasdaq Capital Markets, with the shares expected to begin trading on or around the date of November 13, 2025 under the symbol “CABR”, at which point our common stock will cease to be traded on the OTCQB.

Caring Brands intends to use the net proceeds received from this offering for general and working capital purposes, including but not limited to marketing and sales of its proprietary products, and for the repayment of certain debt.

D. Boral Capital LLC (“D. Boral”) is acting as the sole underwriter in connection with this offering.

A registration statement on Form S-1 relating to the Offering, as amended, was filed with the Securities and Exchange Commission (the “SEC”) (File Number: 333-289767) and was automatically declared effective on October 30, 2025. The Offering is being made only by means of a prospectus. A copy of the final prospectus will be filed with the SEC, which may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022 by email to info@dboralcapital.com, or by calling (212) 970-5150.

Before you invest, you should read the registration statement, the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any offer, solicitation or sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Caring Brands, Inc.

Caring Brands is a wellness consumer products company who offers several over-the-counter (OTC) and cosmetic consumer products. The Company’s product pipeline includes a diverse range of products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, and a jellyfish sting protective suncare line catering to diverse health and wellness needs. The Company’s method of operation ensures that the mechanism of action of all products is established, efficacy is determined through controlled clinical trials, products are protected by issued and filed patents, and products have acceptable commercial stability.

Forward-Looking Statement

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the proposed Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “believe”, “plan”, “expect”, “intend”, “should”, “seek”, “estimate”, “will”, “aim” and “anticipate” or other similar expressions in the prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC, which are available for review at www.sec.gov.

For further information, please contact:

Brian S John

investors@caringbrands.com

(561) 896-7616

UniPin India Launches First-Ever Delhi Metro Campaign: “Spot Us & Win Lakhs of Gaming Credits”
Beko Scales Up Climate Action with Green Electricity and Refurbishment
Las Vegas Kicks Off The Fabulous 5Day Sale Today
Fractal Named a Leader in Customer Analytics by Independent Research Firm
Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (Stratus)
TAGGED:$4,000,000announcesbrandscaringmillionnasdaqNasdaq:CABRnewspricinguplistingUS14216J1097
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
News

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

28/10/2025
The Fabulous Tunnel Walk Debuts at Allegiant Stadium
SRIVARU Motors Unveils Next-Gen Electric Two-Wheelers: The Alive Scooter Series and PRANA Class Motorcycle
Turin Motor Show 1965: the chassis that ignited the Miura legend
Movate and Anzenna Forge Strategic Partnership to Redefine Insider Risk Governance in the AI Era
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?